Regeneron Pharmaceuticals · Stock-Based Compensation

Latest reported$986.70Mperiod endingJun 30, 2026

REGN Stock-Based Comp ($0.00 → $986.70M)

Annual stock-based compensation

High-resolution chart · PNG

REGN stock-based compensation history

Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Regeneron Pharmaceuticals Stock-Based Compensation — Annual fiscal periods (USD)
Period ending	Stock-Based Compensation (USD)
Dec 31, 2025	993,700,000
Dec 31, 2024	982,800,000
Dec 31, 2023	885,000,000
Dec 31, 2022	725,000,000
Dec 31, 2021	601,700,000
Dec 31, 2020	432,000,000
Dec 31, 2019	464,300,000
Dec 31, 2018	427,400,000
Dec 31, 2017	507,277,000
Dec 31, 2016	559,878,000
Dec 31, 2015	459,049,000
Dec 31, 2014	307,238,000
Dec 31, 2013	198,399,000
Dec 31, 2012	94,157,000
Dec 31, 2011	56,094,000
Dec 31, 2010	39,897,000
Dec 31, 2009	31,259,000
Dec 31, 2008	32,523,000
Dec 31, 2007	28,075,000
Dec 31, 2006	0
Dec 31, 2005	0
Dec 31, 2004	0
Dec 31, 2003	0
Dec 31, 2002	0
Dec 31, 2001	0
Dec 31, 2000	0
Dec 31, 1999	0
Dec 31, 1998	0
Dec 31, 1997	0
Dec 31, 1996	0
Dec 31, 1995	0
Dec 31, 1994	0
Dec 31, 1993	0
Dec 31, 1992	0
Dec 31, 1991	0